Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Herpesviridae Infections 1HIV Infections 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Opportunistic Infections 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × Acyclovir × Clear all
NCT00000712 2021-11-04

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
400 enrolled

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Herpesviridae Infections, HIV Infections, AIDS-Related Opportunistic Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡